KPTI Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Karyopharm Therapeutics Inc. had $146M of revenue in fiscal 2025, up 0.6% on the year before. Over five years, revenue changed +6.2% a year on average.
Last close Β· Oct 23, 2026
$0.52
5.2%Hi! I read Karyopharm Therapeutics Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+0.6%
Only a little. Sales grew 0.6% last year.
Does it make a profit?
β134.2%
No. It lost money last year.
Does profit turn into cash?
β51.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Karyopharm Therapeutics Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 2, 2026
Monday Β· in 7 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 14, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Oct 7, 2025 | Q3 '25 | Time not announced | 8-K β |
| Aug 11, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 12, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 5, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Karyopharm Therapeutics Inc. had $146M of revenue in fiscal 2025, up 0.6% on the year before. Over five years, revenue changed +6.2% a year on average. Its operating margin was β62.1%, up 20.1Β pts: of every 100 in sales, about β62 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Karyopharm Therapeutics Inc. lost $196M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$75.4M in fiscal 2025, β51.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Karyopharm Therapeutics Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $229M | $278M | $191M | $109M | $63.7M |
| Debt incl. finance leases | $169M | β | β | β | β |
| Interest coverage | β3.8x | β5.7x | β5.4x | β3.2x | β2.0x |
| Current ratio | 3.7x | 5.3x | 3.4x | 1.7x | 1.1x |
| Quick ratio | 3.7x | 5.2x | 3.3x | 1.6x | 1.1x |
| Total assets | $305M | $358M | $240M | $164M | $108M |
| Total liabilities | $385M | $375M | $377M | $350M | $401M |
| Shareholders' equity | β$79.7M | β$16.7M | β$136M | β$186M | β$293M |
| Net debt (β = net cash) | β$59.3M | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Karyopharm Therapeutics Inc. passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 5 / 7 | 2 / 7 | 3 / 7 | 3 / 7 | 3 / 7 | 3 / 7 | 2 / 7 | 2 / 7 |
| Accruals ratio | β14.0% | β30.6% | β7.4% | β2.8% | β11.9% | β5.5% | β4.7% | β16.8% | 25.2% | β88.5% |
| Altman Z'' | 2.84 | β7.55 | β3.23 | β8.59 | β10.09 | β10.63 | β9.74 | β19.68 | β33.88 | β58.62 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.2M | $1.6M | $30.3M | $40.9M | $108M | $210M | $157M | $146M | $145M | $146M |
| Research and development | $86.9M | $107M | $161M | $122M | $151M | $161M | $149M | $139M | $143M | $126M |
| Operating income | β$111M | β$131M | β$180M | β$189M | β$172M | β$98.3M | β$142M | β$130M | β$119M | β$90.7M |
| Interest expense | β | β | $2.5M | $15.6M | $27.1M | $26.0M | $25.0M | $23.8M | $37.4M | $45.8M |
| Pretax income | β$109M | β$129M | β$178M | β$200M | β$196M | β$124M | β$165M | β$143M | β$76.4M | β$196M |
| Income tax | $0.1M | $0.1M | $0.0M | $0.0M | $0.3M | $0.3M | $0.4M | $0.3M | $0.1M | $0.0M |
| Net income | β$110M | β$129M | β$178M | β$200M | β$196M | β$124M | β$165M | β$143M | β$76.4M | β$196M |
| Diluted EPS | β$2.92 | β$2.81 | β$3.14 | β$3.22 | β$2.72 | β$1.65 | β$2.02 | β$18.79 | β$14.00 | β$17.93 |
| Diluted shares | 0.04B | 0.05B | 0.00B | 0.06B | 0.07B | 0.08B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$84.4M | β$73.7M | β$159M | β$191M | β$160M | β$107M | β$150M | β$92.7M | β$127M | β$75.4M |
| Capital expenditure | $0.1M | $0.1M | $2.4M | $0.2M | $0.1M | $0.2M | $0.1M | $0.0M | $0.1M | $0.0M |
| Free cash flow | β$84.5M | β$73.8M | β$161M | β$191M | β$160M | β$107M | β$150M | β$92.7M | β$128M | β$75.4M |
| Depreciation and amortization | $0.7M | $0.7M | $0.7M | $1.0M | $1.0M | $0.8M | $0.6M | $0.5M | $0.3M | $0.3M |
| Stock-based compensation | $22.3M | $20.4M | $17.3M | $15.3M | $24.4M | $29.8M | $35.4M | $21.7M | $18.4M | $14.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $130M | $146M | $328M | $262M | $249M | $229M | $278M | $191M | $109M | $63.7M |
| Total debt | β | β | β | β | β | $169M | β | β | β | β |
| Current assets | $132M | $148M | $335M | $279M | $277M | $276M | $350M | $234M | $156M | $103M |
| Current liabilities | $16.5M | $49.5M | $46.9M | $46.4M | $60.2M | $73.7M | $65.9M | $69.5M | $92.3M | $92.1M |
| Inventory | β | β | β | $0.3M | $2.6M | $4.1M | $4.2M | $3.0M | $4.7M | $4.0M |
| Property and equipment, net | $2.8M | $2.2M | $3.9M | $3.0M | $2.2M | $1.6M | $1.1M | $0.6M | $0.4M | $0.1M |
| Total assets | $180M | $180M | $341M | $295M | $313M | $305M | $358M | $240M | $164M | $108M |
| Total liabilities | $18.1M | $50.8M | $158M | $245M | $263M | $385M | $375M | $377M | $350M | $401M |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $162M | $129M | $183M | $49.8M | $50.5M | β$79.7M | β$16.7M | β$136M | β$186M | β$293M |
| Margins | ||||||||||
| Operating margin | β71,903.9% | β8,133.2% | β593.0% | β462.9% | β159.0% | β46.8% | β90.5% | β88.7% | β82.2% | β62.1% |
| EBITDA margin | β71,438.3% | β8,088.8% | β590.5% | β460.5% | β158.1% | β46.5% | β90.1% | β88.3% | β82.0% | β61.9% |
| Net margin | β71,153.9% | β8,036.4% | β588.1% | β488.1% | β181.6% | β59.1% | β105.2% | β98.0% | β52.6% | β134.2% |
| FCF margin | β54,844.8% | β4,596.8% | β532.3% | β467.1% | β148.4% | β51.2% | β95.3% | β63.5% | β87.9% | β51.6% |
| Returns | ||||||||||
| Return on capital employed | β67.6% | β99.8% | β61.1% | β76.1% | β68.0% | β42.4% | β48.7% | β75.8% | β165.5% | β554.6% |
| Return on equity | β67.5% | β88.4% | β114.1% | β171.4% | β391.3% | β | β | β | β | β |
| Return on assets | β60.7% | β71.5% | β68.4% | β62.7% | β64.6% | β40.1% | β49.8% | β47.8% | β37.8% | β143.7% |
| Return on tangible equity | β67.5% | β99.6% | β97.4% | β401.0% | β388.3% | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | 942.2% | 1,790.1% | 34.8% | 164.3% | 94.1% | β25.1% | β7.0% | β0.5% | 0.6% |
| Share count change | β | 22.3% | β99.9% | 108,975.7% | 16.3% | 4.4% | β99.9% | β90.7% | 11.8% | 28.2% |
| Financial health | ||||||||||
| Interest coverage | β | β | β72.2x | β12.1x | β6.3x | β3.8x | β5.7x | β5.4x | β3.2x | β2.0x |
| Current ratio | 8.0x | 3.0x | 7.1x | 6.0x | 4.6x | 3.7x | 5.3x | 3.4x | 1.7x | 1.1x |
| Quick ratio | 8.0x | 3.0x | 7.1x | 6.0x | 4.5x | 3.7x | 5.2x | 3.3x | 1.6x | 1.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 45.5% | 3.9% | 7.8% | 0.5% | 0.1% | 0.1% | 0.1% | 0.0% | 0.1% | 0.0% |
| Stock comp / revenue | 14,469.5% | 1,271.3% | 56.9% | 37.4% | 22.6% | 14.2% | 22.5% | 14.9% | 12.7% | 9.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 5.0 | 2.0 | 3.0 | 3.0 | 3.0 | 3.0 | 2.0 | 2.0 |
| Altman Z'' | 2.8 | β7.5 | β3.2 | β8.6 | β10.1 | β10.6 | β9.7 | β19.7 | β33.9 | β58.6 |
| Accruals ratio | β14.0% | β30.6% | β7.4% | β2.8% | β11.9% | β5.5% | β4.7% | β16.8% | 25.2% | β88.5% |
Source: SEC EDGAR XBRL filings (CIK 0001503802). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
